KBS Real Estate Investment Trust III Announces $11.73 NAV Per Share

December 18, 2017

KBS Real Estate Investment Trust III Announces $11.73 NAV Per Share

December 14, 2017 | James Sprow | Blue Vault

Office building close up with large glass windows.

KBS REIT III announced a revised NAV per share of $11.73 as of December 6, 2017. The previously estimated value per share as of December 9, 2016, was $10.63. The new NAV per share represents an increase of 10.3% in one year.

The REIT’s estimated value per share was determined in accordance with IPA’s Practice Guideline 2013-01. Duff & Phelps, an independent, third-party real estate valuation firm, was engaged to provide a calculation of the range in estimated value per share of common stock as of December 6, 2017. Duff & Phelps based the range in estimated value per share upon:

  • Appraisals of 28 of KBS REIT III’s consolidated real estate properties owned as of September 30, 2017, performed by Duff & Phelps, and one property under contract to sell as of December 6, 2017, which was valued at its contractual sales price less estimated disposition costs and fees
  • Valuations performed by the Advisor of KBS REIT III’s other assets and liabilities
  • A reduction to KBS III’s net asset value for deferred financing costs related to a portfolio loan facility that closed subsequent to September 30, 2017

The estimated value per share did not include an enterprise (portfolio) premium or discount.

KBS REIT III’s board of directors approved $11.73 which represents the mid-range value of the range in estimated value per share calculated by Duff & Phelps.



Learn more about KBS Capital Markets Group on the Blue Vault Sponsor Focus page.

Click Here


KBS Strategic Opportunity REIT Announces NAV and $3.61 Special Dividend

KBS Strategic Opportunity REIT to Sell 11 Properties for $804 Million

KBS Debuts KBSDirect.com Real Estate Investment Portal


Go Back
Matthew C. Strife
Blue Vault Services
April 11, 2016

Blue Vault's services are without question great resources for the review of the nontraded products offered.